Goldman Sachs
INFI

Goldman Sachs’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Goldman Sachs’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-74,000
Closed -$390K – 7313
2016
Q1 		$390K Buy
+74,000
New +$453K ﹤0.01% 5005
2015
Q4 		– Sell
-30,000
Closed -$253K – 7405
2015
Q3 		$253K Buy
+30,000
New +$277K ﹤0.01% 5770
2015
Q1 		– Sell
-463,800
Closed -$7.83M – 7343
2014
Q4 		$7.83M Buy
463,800
+214,200
+86% +$3.12M ﹤0.01% 2560
2014
Q3 		$3.35M Buy
249,600
+69,200
+38% +$824K ﹤0.01% 3417
2014
Q2 		$2.3M Sell
180,400
-151,700
-46% -$1.58M ﹤0.01% 3850
2014
Q1 		$3.95M Buy
332,100
+184,300
+125% +$2.47M ﹤0.01% 3293
2013
Q4 		$2.04M Sell
147,800
-192,100
-57% -$2.71M ﹤0.01% 4038
2013
Q3 		$5.92M Buy
339,900
+325,400
+2,244% +$6.23M ﹤0.01% 2757
2013
Q2 		$235K Buy
+14,500
New +$449K ﹤0.01% 5482

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's INFI Position: Q1 2023 in Review

Goldman Sachs sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2023, closing a stake of 25,367 shares — an estimated $14.1K sold.

Goldman Sachs first reported a position in INFI in Q2 2013 and held it in 32 quarters. The position peaked at $61.2M in Q2 2015. 53 funds tracked by Wall St. Rank hold INFI as of Q1 2023.

  • Goldman Sachs reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 25,367 Infinity Pharmaceuticals, Inc. shares in Q1 2023, an estimated $14.1K.
  • Goldman Sachs first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 32 quarters.
  • Goldman Sachs's Infinity Pharmaceuticals, Inc. position peaked at $61.2M in Q2 2015.
  • 53 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.